Your browser doesn't support javascript.
loading
Drugs' development in acute heart failure: what went wrong?
Teneggi, Vincenzo; Sivakumar, Nithy; Chen, Deborah; Matter, Alex.
Affiliation
  • Teneggi V; D3 (Drug Discovery and Development), A*STAR, Singapore, Singapore. vteneggi@d3.a-star.edu.sg.
  • Sivakumar N; D3 (Drug Discovery and Development), A*STAR, Singapore, Singapore.
  • Chen D; D3 (Drug Discovery and Development), A*STAR, Singapore, Singapore.
  • Matter A; Experimental, Therapeutics Centre, A*STAR, Singapore, Singapore.
Heart Fail Rev ; 23(5): 667-691, 2018 09.
Article in En | MEDLINE | ID: mdl-29736812
Acute heart failure (AHF) is a major burden disease, with a complex physiopathology, unsatisfactory diagnosis, treatment and a very poor prognosis. In the last two decades, a number of drugs have progressed from preclinical to early and late clinical development, but only a few of them have been approved and added to a stagnant pharmacological armamentarium. We have reviewed the data published on drugs developed for AHF since early 2000s, trying to recognise factors that have worked for a successful approval or for the stoppage of the program, in an attempt to delineate future trajectories for AHF drug development. Our review has identified limitations at both preclinical and clinical levels. At the preclinical level, the major shortcoming is represented by animal models looking at short-term endpoints which do not recapitulate the complexity of the human disease. At the clinical level, the main weakness is given by the disconnect between short-term endpoints assessed in the early stage of drug development, and medium-long-term endpoints requested in Phase 3 for regulatory approval. This is further amplified by the lack of validation and standardisation of short- and long-term endpoints; absence of predictive biomarkers; conduct of studies on heterogeneous populations; and use of different eligibility criteria, time of assessments, drug schedules and background therapies. Key goals remain a better understanding of AHF and the construction of a successful drug development program. A reasonable way to move forward resides in a strong collaboration between main stakeholders of therapeutic innovation: scientific community, industry and regulatory agencies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiotonic Agents / Drug Development / Heart Failure Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Heart Fail Rev Journal subject: CARDIOLOGIA Year: 2018 Document type: Article Affiliation country: Singapore Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiotonic Agents / Drug Development / Heart Failure Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Heart Fail Rev Journal subject: CARDIOLOGIA Year: 2018 Document type: Article Affiliation country: Singapore Country of publication: United States